Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: Peptide compositions having bacteriocidal peptides are described. Also described is a method of bacterial infections using compositions comprising bacteriocidal peptides or modified peptides with structural relationships to cathelicidins.

Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: Peptide compositions having bacteriocidal peptides are described. Also described is a method of bacterial infections using compositions comprising bacteriocidal peptides or modified peptides with structural relationships to cathelicidins.

Abstract: This disclosure is related to the peptide antagonist of LL-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of LL-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain LL-37's antibacterial activity.

Abstract: This disclosure is related to the peptide antagonist of LL-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of LL-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain LL-37's antibacterial activity.

Abstract: Compositions and methods for the treatment of norovirus infection are disclosed.

Abstract: Compositions and methods for the treatment of norovirus infection are disclosed.

Abstract: Compositions and methods for the treatment of norovirus infection are disclosed.

Abstract: The invention provides antiviral compounds and compositions comprising a viral specific oligonucleotide. Also provided are methods to inhibit or treat viral infections with the compounds or compositions of the invention.

Abstract: The invention provides antiviral compounds and compositions comprising a viral specific oligonucleotide. Also provided are methods to inhibit or treat viral infections with the compounds or compositions of the invention.

Abstract: The invention provides methods and compositions for polymerizing a particular nucleotide with a polymerase. In general, the method involves (a) forming a mixture of a polymerase and a nucleoside triphosphate (NTP) comprising &agr;, &bgr; and &ggr; phosphates and a &ggr;-phosphate phosphoester-linked functional group; and incubating the mixture under conditions wherein the polymerase catalyzes cleavage of the NTP between the &agr; and &bgr; phosphates, liberating a pyrophosphate comprising the functional group and polymerizing the resultant nucleoside monophosphate, i.e. incorporates the nucleoside monophosphate in a nascent polynucleotide. A variety of functional groups compatible with the polymerization reaction are provided.

Abstract: Non-template 3' nucleotide addition to a transcript is reduced by transcribing a transcript from a template comprising an ultimate and/or penultimate 5' ribose having a C'2 substituent such as methoxy, which reduces non-template 3' nucleotide addition to the transcript. The methods are shown to be applicable to a wide variety of polymerases, including Taq, T7 RNA polymerase, etc.